Dbv Technologies ADR (DBVT) Stock Price, Quote & News

Company Profile

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. The company's product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. Its earlie...

Industry: Biotechnology

Sector: Healthcare

Phone: 33 1 55 42 78 78

Website: www.dbv-technologies.com

Address:

BAtiment IRO, 107 Av. de la REpublique, Châtillon, France

Zamboni18 Mar. 12 at 1:40 PM

$DBVT

0 · Reply

medguy Mar. 12 at 4:16 AM

Looking for bounce $DBVT

0 · Reply

focafoca99 Mar. 3 at 10:47 PM

$DBVT dropped a voting-rights/share-count update.

0 · Reply

kriks2611 Mar. 2 at 9:56 PM

$DBVT

0 · Reply

notreload_ai Mar. 2 at 4:10 PM

$DBVT reveals new VITESSE Phase 3 data at AAAAI 2026: 83% of kids on VIASKIN Peanut Patch increased safe peanut dose vs 48% on placebo, with excellent safety. https://notreload.xyz/kids-tolerate-more-peanut-with-viaskin-patch-in-landmark-study/

0 · Reply

OpenOutcrier Mar. 2 at 1:37 PM

$DBVT (+1.4% pre) Phase 3 VITESSE data highlighted by DBV Technologies https://ooc.bz/l/95114

0 · Reply

AlertsAndNews Feb. 28 at 8:46 PM

$DBVT DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting "Approximately 83% of children treated with the VIASKIN® Peanut Patch increased their eliciting dose at month 12, compared to approximately 48% in the placebo group Approximately 60% of children treated with the VIASKIN® Peanut Patch increased their eliciting dose by at least two doses at month 12, compared to 23% in the placebo group"

0 · Reply

StockNews_Live Feb. 28 at 7:25 PM

$DBVT DBV Technologies announced additional positive data from the successful Phase 3 VITESSE clinical trial at the American Academy of Allergy, Asthma, and Immunology (AAAAI) 2026 Annual Meeting. Approxima…

0 · Reply

Lalalilala Feb. 25 at 8:20 PM

$DBVT This is bad news, coming just two days before a Phase 3 data presentation. Run before it drops to $8 on Monday. 😩

0 · Reply

Lalalilala Feb. 24 at 8:59 PM

$DBVT up . Spéculation thursday expect 26$.

0 · Reply

DBV Technologies to Participate in Upcoming March Investor Conferences

DBVT

2026-03-02T11:16:31.000Z - 18 days ago

DBV Technologies Peanut Patch Meets Primary Endpoint In Phase 3 VITESSE Study

2026-03-01T16:52:03.000Z - 18 days ago

DBVT Shares Promising Phase 3 Trial Results for Viaskin Peanut

Feb 28, 2026, 2:25 PM EST - 19 days ago

DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting

DBVT

Feb 10, 2026, 4:30 PM EST - 5 weeks ago

DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI 2026 Annual Meeting

DBVT

Feb 5, 2026, 4:30 PM EST - 6 weeks ago

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of January 31, 2026

DBVT

Jan 16, 2026, 6:11 PM EST - 2 months ago

DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing

DBVT

Jan 12, 2026, 4:00 PM EST - 2 months ago

Information Regarding the Total number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025

DBVT

Jan 5, 2026, 4:00 PM EST - 2 months ago

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025

DBVT

Dec 17, 2025, 8:49 AM EST - 3 months ago

Peanut Allergy Patch For Kids? DBV Technologies Advances Toward FDA Filing

DBVT

Dec 16, 2025, 10:10 PM EST - 3 months ago

DBV Technologies S.A. (DBVT) Discusses Positive Phase III VITESSE Trial Results for Peanut Allergy Patch in Young Children Transcript

DBVT

Nov 11, 2025, 11:50 PM EST - 4 months ago

DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years

DBVT

Nov 4, 2025, 4:30 PM EST - 4 months ago

DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

DBVT

Nov 3, 2025, 4:30 PM EST - 4 months ago

DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer

DBVT

Oct 30, 2025, 4:30 PM EDT - 5 months ago

DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors

DBVT

Oct 30, 2025, 3:00 AM EDT - 5 months ago

DBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientific Meeting

DBVT

Oct 29, 2025, 6:47 PM EDT - 5 months ago

DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq

DBVT

Sep 18, 2025, 4:30 PM EDT - 6 months ago

DBV Technologies Announces Resignation of Board Member

DBVT

Sep 5, 2025, 4:30 PM EDT - 6 months ago

DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq

DBVT

Jul 29, 2025, 4:17 PM EDT - 8 months ago

DBV Technologies announces filing of 2025 Half-Year Report ― Conditions for accessing or consulting the Report

DBVT

Jul 29, 2025, 4:08 PM EDT - 8 months ago

DBV Technologies Reports Second Quarter and Half-Year 2025 Financial Results

DBVT

Jul 28, 2025, 4:30 PM EDT - 8 months ago

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

DBVT

Jul 22, 2025, 4:30 PM EDT - 8 months ago

DBV Technologies Announces Appointment of James Briggs as Chief Human Resources Officer

DBVT

Jun 25, 2025, 4:15 PM EDT - 9 months ago

DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old

DBVT

Jun 12, 2025, 4:05 PM EDT - 10 months ago

DBV Technologies to Participate in Upcoming EAACI Congress 2025

DBVT

Jun 11, 2025, 4:30 PM EDT - 10 months ago

DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting

DBVT

Jun 3, 2025, 4:30 PM EDT - 10 months ago

DBV Technologies announces the filing of an addendum to the 2024 Universal Registration Document

DBVT

May 15, 2025, 4:30 PM EDT - 11 months ago

Combined General Meeting of June 11, 2025

DBVT

May 5, 2025, 4:30 PM EDT - 11 months ago

DBV Technologies to Participate in the Citizens JMP Life Sciences Conference

DBVT

Apr 30, 2025, 4:00 PM EDT - 11 months ago

DBV Technologies Reports First Quarter 2025 Financial Results

DBVT

Apr 11, 2025, 4:30 PM EDT - 1 year ago

DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document

DBVT

Mar 28, 2025, 11:09 AM EDT - 1 year ago

DBV Technologies ADRs Rise After Up to $306.9M in New Financing

DBVT

Mar 27, 2025, 10:30 PM EDT - 1 year ago

DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved

DBVT

Mar 24, 2025, 2:30 AM EDT - 1 year ago

DBV Technologies Secures Agreement with FDA on Safety Exposure Data Required for BLA for Viaskin® Peanut Patch in 4–7-year-olds, Accelerating the Timeline for a BLA Filing Submission to 1H 2026, & Reports 2024 Unaudited Financial Results

DBVT

Feb 25, 2025, 4:01 PM EST - 1 year ago

DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress

DBVT

Dec 12, 2024, 9:59 AM EST - 1 year ago

DBV Aligns With FDA On Accelerated Approval For Viaskin Peanut Patch In Younger Kids

DBVT

Dec 11, 2024, 4:05 PM EST - 1 year ago

DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old

DBVT

Nov 11, 2024, 4:30 PM EST - 1 year ago

DBV Technologies Announces Plan to Implement ADS Ratio Change

DBVT

Nov 6, 2024, 4:30 PM EST - 1 year ago

DBV Technologies Reports Third Quarter 2024 Financial Results

DBVT

Oct 22, 2024, 4:45 PM EDT - 1 year ago

DBV Announces Positive Regulatory Updates for the Viaskin® Peanut Patch in the United States and Europe

DBVT

Oct 18, 2024, 4:30 PM EDT - 1 year ago

DBV Technologies to Participate in Upcoming ACAAI 2024 Congress

DBVT

Sep 23, 2024, 4:30 PM EDT - 1 year ago

DBV Technologies Completes Screening for the VITESSE Phase 3 Clinical Trial

DBVT

Sep 4, 2024, 4:30 PM EDT - 1 year ago

DBV Technologies to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

DBVT

Jul 30, 2024, 10:03 PM EDT - 1 year ago

DBV Technologies S.A. (DBVT) Q2 2024 Earnings Call Transcript

DBVT

Jul 30, 2024, 5:30 PM EDT - 1 year ago

DBV Technologies Announces Filing of 2024 Half-Year Report ― Conditions for Accessing or Consulting the Report

DBVT

Jul 30, 2024, 4:30 PM EDT - 1 year ago

DBV Technologies Provides Updates on the Viaskin Peanut Program in Children and Toddlers and Reports Second Quarter and Half-Year 2024 Financial Results

DBVT

Jul 29, 2024, 1:30 AM EDT - 1 year ago

DBV Technologies to Report Second Quarter 2024 Financial Results and Business Update on July 30, 2024

DBVT

Jun 5, 2024, 4:30 PM EDT - 1 year ago

DBV Technologies to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

DBVT

May 30, 2024, 4:30 PM EDT - 1 year ago

DBV Technologies to Participate in Upcoming EAACI 2024 Congress

DBVT

May 16, 2024, 4:30 PM EDT - 2 years ago

DBV Technologies Announces Results of its 2024 Combined General Meeting

DBVT

May 9, 2024, 4:30 PM EDT - 2 years ago

DBV Technologies to Participate in Upcoming Investor Conferences

May 7, 2024, 4:30 PM EDT - 2 years ago

DBV Technologies Reports First Quarter 2024 Financial Results and Business Update

Zamboni18 Mar. 12 at 1:40 PM

$DBVT

0 · Reply

medguy Mar. 12 at 4:16 AM

Looking for bounce $DBVT

0 · Reply

focafoca99 Mar. 3 at 10:47 PM

$DBVT dropped a voting-rights/share-count update.

0 · Reply

kriks2611 Mar. 2 at 9:56 PM

$DBVT

0 · Reply

notreload_ai Mar. 2 at 4:10 PM

0 · Reply

OpenOutcrier Mar. 2 at 1:37 PM

$DBVT (+1.4% pre) Phase 3 VITESSE data highlighted by DBV Technologies https://ooc.bz/l/95114

0 · Reply

AlertsAndNews Feb. 28 at 8:46 PM

0 · Reply

StockNews_Live Feb. 28 at 7:25 PM

0 · Reply

Lalalilala Feb. 25 at 8:20 PM

$DBVT This is bad news, coming just two days before a Phase 3 data presentation. Run before it drops to $8 on Monday. 😩

0 · Reply

Lalalilala Feb. 24 at 8:59 PM

$DBVT up . Spéculation thursday expect 26$.

0 · Reply

WolferG Feb. 24 at 12:40 PM

$DBVT Positive Clinical Progress & Regulatory Moves.

0 · Reply

WolferG Feb. 24 at 12:39 PM

$DBVT

0 · Reply

BillionerOfKing Feb. 23 at 8:48 PM

$DBVT Current Stock Price: $21.14

1 · Reply

RodneyHammons200 Feb. 21 at 7:15 AM

$DBVT DBV Technologies develops allergy immunotherapy treatments. Clinical trial outcomes drive valuation. Funding risk remains significant.

0 · Reply

FadeChaser Feb. 18 at 9:17 AM

$DBVT Rare disease biotech where regulatory pathways define upside.

1 · Reply

F_75 Feb. 13 at 2:53 PM

$DBVT read https://finance.yahoo.com/news/dbv-technologies-details-viaskin-peanut-121318017.html and you can find out where the journey with DBVT will go from 2027

0 · Reply

OfficialStocktwitsUser Feb. 12 at 11:32 PM

$DBVT RSI: 40.31, MACD: 0.8535 Vol: 1.39, MA20: 22.30, MA50: 19.72 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

BioTechHealthX Feb. 12 at 5:09 PM

$DBVT Long before “exposure management” became a buzzword in tech, DBV Technologies was already chasing “exposure” in immunology—controlled micro-exposures through the skin via the VIASKIN platform. Learn the background behind the epicutaneous immunotherapy story driving DBVT stock interest. https://biotechhealthx.com/biotech-news/dbv-technologies-dbvt-didnt-chase-a-fad-it-built-a-category-the-peanut-allergy-patch/

0 · Reply

BioTechHealthX Feb. 12 at 8:58 AM

$MBRX $ACHV $AVTX $DBVT $MNMD 2026 is packed with Phase 2 results, Phase 3 topline data, and FDA decision dates that can reprice biotech stocks fast. This watchlist screens NYSE/NASDAQ names under $2B market cap and ranks the top 5 by market cap—built for investors hunting asymmetric upside. https://biotechhealthx.com/biotech-news/top-5-best-biotech-micro-caps-with-major-clinical-catalysts-in-2026/

0 · Reply

OpenOutcrier Feb. 11 at 1:48 PM

$DBVT (-5.7% pre) DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI 2026 Annual Meeting https://ooc.bz/l/92943

0 · Reply

Elegant_Confusion Feb. 4 at 3:28 PM

$DBVT no that is wrong! DBVT is developing a patch for desensitization to peanut allergies, with successful trials in children age 4 to 7, and impending trials for toddlers age 1 to 4. Several other companies are developing vaccines for peanut allergies using different approahes. For all of them, the regulatory path is indeed challenging, and commercial uptake uncertain, especially with all the vaccine hesitancy we have now.

0 · Reply

RiskAtlas Feb. 4 at 2:06 PM

$DBVT is a biotech developing a vaccine for peanut allergy; its regulatory path has been challenging, and commercial uptake remains uncertain.

0 · Reply

Market Cap	1.08B
Revenue (ttm)	4.15M
Net Income (ttm)	-113.92M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-2,745.06%
Debt to Equity Ratio	0.00

Volume	129,200
Avg Vol	347,148
Day's Range	N/A - N/A
Shares Out	55.67M
Stochastic %K	15%
Beta	-0.97
Analysts	Strong Sell
Price Target	$39.99